Chinese clinical-stage biopharmaceutical firm Genor Biopharma on Monday announced that it has garnered $160 million in a Series B round of financing led by Asia-focused private equity major Hillhouse Capital Group.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
